Profile: Radius Health Inc (RDUS.A)
14 Jun 2019
Radius Health, Inc., incorporated on February 4, 2008, is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company's lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
The Company's clinical pipeline also includes an investigational abaloparatide transdermal patch, or abaloparatide-TD, for potential use in the treatment of women with postmenopausal osteoporosis. The Company is focused on completing the manufacturing scale-up, production, and other activities required for the initiation of a pivotal bioequivalence study for abaloparatide-TD. In addition, the Company is evaluating its investigational product candidate, RAD1901, a selective estrogen receptor down-regulator/degrader (SERD) for potential use in the treatment of hormone-driven and/or hormone-resistant breast cancer, as well as for potential use in the treatment of vasomotor symptoms in postmenopausal women. Its clinical pipeline also includes internally developed investigational product candidate, RAD140, a non-steroidal selective androgen receptor modulator (SARM) under investigation for potential use in the treatment of breast cancer.
Abaloparatide is an investigational therapy for the potential treatment of women with postmenopausal osteoporosis who are at an increased risk for a fracture. Abaloparatide is a synthetic peptide analog that engages the parathyroid hormone receptor (PTH1 receptor), and was selected for clinical development based on its potential for favorable bone building activity. The Company holds worldwide commercialization rights to abaloparatide-SC, except for Japan. It holds worldwide commercialization rights to the abaloparatide-TD technology.
RAD1901 is a SERD that at high doses is being evaluated for potential use as an oral non-steroidal treatment for hormone-driven and/or hormone-resistant, breast cancer. The Company holds worldwide commercialization rights to RAD1901. RAD1901 is being investigated in postmenopausal women with advanced estrogen receptor positive (ER-positive), and human epidermal growth factor receptor 2-negative (HER2-negative) breast cancer, the common form of the disease. RAD140 is a nonsteroidal SARM. The Company holds worldwide commercialization rights to RAD140.
Radius Health Inc
950 Winter St
WALTHAM MA 02451-1424